United Therapeutics (UTHR) Depreciation and Depletion (2024 - 2026)

United Therapeutics (UTHR) has 3 years of Depreciation and Depletion data on file, last reported at $21.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 10.2% year-over-year to $21.6 million; the trailing twelve-month figure through Mar 2026 stood at $86.7 million (up 13.48% YoY), and the FY2025 full-year result was $84.7 million, up 18.3% from the prior year.
• Depreciation and Depletion retreated to $21.6 million in Q1 2026, from $22.7 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $22.7 million in Q4 2025 to a low of $14.8 million in Q1 2024.
• A 3-year average of $19.8 million and a median of $19.6 million in 2025 frame the typical range for Depreciation and Depletion.
• Across the five-year window, Depreciation and Depletion surged 32.43% in 2025 and gained 10.2% in 2026, its largest moves.
• Tracing UTHR's Depreciation and Depletion over 3 years: stood at $19.4 million in 2024, then grew by 17.01% to $22.7 million in 2025, then retreated by 4.85% to $21.6 million in 2026.
• Business Quant data shows UTHR's Depreciation and Depletion at $21.6 million in Q1 2026, $22.7 million in Q4 2025, and $21.5 million in Q3 2025.